Matthew Weston
Stock Analyst at UBS
(4.31)
# 1,271
Out of 4,339 analysts
330
Total ratings
72.2%
Success rate
10.5%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €52.00 | $37.82 | +37.49% | 15 | May 13, 2026 | |
| ETR: MRK Merck KGaA | Maintained: Buy | €150.00 | $128.35 | +16.87% | 34 | May 13, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | CHF 384.00 → CHF 376.00 | $331.20 | +13.53% | 55 | May 13, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 332.00 | $288.35 | +15.14% | 26 | May 8, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 116.00 | $118.44 | -2.06% | 44 | May 8, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,600p | $13,960.00 | +26.07% | 65 | Apr 30, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,940p | $1,925.00 | +0.78% | 14 | Apr 30, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €88.00 | $76.32 | +15.30% | 14 | Apr 24, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Hold | €240.00 | $233.00 | +3.00% | 28 | Apr 23, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Maintained: Hold | €220.00 | $171.70 | +28.13% | 15 | Apr 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 200.00 | $158.35 | +26.30% | 10 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $119.72 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 750.00 | $491.50 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | $161.40 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $310 | $44.19 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $150.80 | n/a | 1 | Jul 5, 2017 |
Bayer Aktiengesellschaft
May 13, 2026
Maintained: Buy
Price Target: €52.00
Current: $37.82
Upside: +37.49%
Merck KGaA
May 13, 2026
Maintained: Buy
Price Target: €150.00
Current: $128.35
Upside: +16.87%
Roche Holding AG
May 13, 2026
Maintained: Buy
Price Target: CHF 384.00 → CHF 376.00
Current: $331.20
Upside: +13.53%
Novo Nordisk A/S
May 8, 2026
Maintained: Hold
Price Target: kr 332.00
Current: $288.35
Upside: +15.14%
Novartis AG
May 8, 2026
Maintained: Hold
Price Target: CHF 116.00
Current: $118.44
Upside: -2.06%
AstraZeneca PLC
Apr 30, 2026
Maintained: Buy
Price Target: 17,600p
Current: $13,960.00
Upside: +26.07%
GSK plc
Apr 30, 2026
Maintained: Hold
Price Target: 1,940p
Current: $1,925.00
Upside: +0.78%
Sanofi
Apr 24, 2026
Maintained: Hold
Price Target: €88.00
Current: $76.32
Upside: +15.30%
Sartorius Aktiengesellschaft
Apr 23, 2026
Maintained: Hold
Price Target: €240.00
Current: $233.00
Upside: +3.00%
Sartorius Stedim Biotech S.A.
Apr 17, 2026
Maintained: Hold
Price Target: €220.00
Current: $171.70
Upside: +28.13%
Apr 13, 2026
Maintained: Buy
Price Target: CHF 200.00
Current: $158.35
Upside: +26.30%
Nov 1, 2024
Maintained: Buy
Price Target: $125
Current: $119.72
Upside: n/a
Jan 27, 2022
Maintained: Buy
Price Target: CHF 750.00
Current: $491.50
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: $161.40
Upside: n/a
Nov 2, 2018
Maintained: Hold
Price Target: $310
Current: $44.19
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $150.80
Upside: n/a